Daily Cancer News

OMNI Health Media is a leading online provider of Daily Cancer News. OMNI’s Daily Cancer News provides summaries of new treatment strategies as they are discovered and reported by physicians and scientists around the world. Our mission is to provide this news, including results of recent clinical trials evaluating cancer therapies and supportive care strategies, to better educate patients and their caregivers, ensuring timely access to the best cancer care available.

CancerConnect Cancer Commuity & Discussions

Share


Latest Cancer News


Risk of Breast Cancer Recurrence Doesn’t Increase with TNF Inhibitor Use (August 28, 2014)

According to the results of a recently published study from Swedish investigators treatment with tumor necrosis factor inhibitors (TNF) does not appear to increase the rate of breast cancer recurrence... Continue Reading

Advaxis and Merck Form Collaboration to Evaluate Investigational Combination of Two Novel Immunotherapy Candidates for Advanced Prostate Cancer (August 27, 2014)

Advaxis, Inc.a clinical-stage biotechnology company developing cancer immunotherapies, has entered into a clinical trial collaboration agreement with Merck to evaluate the safety and efficacy of ADXS-PSA... Continue Reading

Doctors find that Cholesterol Lowering Statin Drugs may Improve Survival From Colon Cancer (August 26, 2014)

According to a new U.K. study, statins, which are widely used cholesterol-lowering drugs, appear to improve colon cancer survival.  The study found that overall, colon cancer patients who took statins... Continue Reading

FDA Approves New Treatment Options for Low Grade Lymphomas and Chronic Lymphocytic Leukemia (August 25, 2014)

Gilead Sciences has confirmed FDA approval of Zydelig (idelalisib) for relapsed chronic lymphocytic leukemia (CLL), follicular lymphoma (FL) and small lymphocytic lymphoma (SLL). Non-Hodgkin’s lymphoma... Continue Reading

Risks May Outweigh Benefits in Surveillance Screening of Elderly with Colon Cancer History (August 22, 2014)

In a recent study published in the Journal of the American Medical Association Internal Medicine, researchers reported that patients over 75 with a history of colon polyps or cancer undergoing surveillance... Continue Reading

Velcade Approved for Retreatment in Multiple Myeloma (August 21, 2014)

The U.S. Food and Drug Administration (FDA) has approved Velcade® (bortezomib) for the retreatment of adult patients with multiple myeloma who had previously responded to Velcade therapy and relapsed... Continue Reading

Exercise & Diet Rich in Fish May Help Prevent Colon Cancer’s Return (August 20, 2014)

A new study suggests that regular exercise and a diet that includes fish may help colon cancer patients improve their odds of avoiding a cancer recurrence. (1) The likelihood that patients will suffer... Continue Reading

Aromasin is New Treatment Option for Young Women With Hormone-sensitive Breast Cancer (August 19, 2014)

The results of a recently completed clinical study presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago and now published online in the New England Journal of Medicine... Continue Reading

Scientific Review Suggests Aspirin Significantly Cuts Cancer Rates (August 18, 2014)

A recent review of several studies confirms that taking a small daily dose of aspirin significantly reduces the risk of developing – or dying from several kinds of cancer.(1) Several clinical studies... Continue Reading

New Online Support Group for People Affected by Gastrointestinal Conditions: IBS, Crohn’s, UC, GERD, Cancer and More (August 14, 2014)

Are you suffering from a gastrointestinal (GI) tract condition? You are not alone! TheGIConnection is now available for patients, caregivers, and health consumers as an up to date online information resource... Continue Reading

OMNI-Connect Gets National Recognition as Valuable Social Media Solution in Medicine (August 13, 2014)

Fort Worth TX/Sun Valley ID – OMNI Health Media announces national recognition of its online support communities, TheGIConnection,TheRAConnection, and Cancer Connect, as valuable resources for... Continue Reading

Your Questions Answered: Polycythemia Vera, Essential Thrombocythemia and Myelofibrosis (August 13, 2014)

 CancerConnect Presents: Ask the Expert with Dr. Mesa Ruben A. Mesa, MD recently participated in the CancerConnect guest moderator series on myeloproliferative neoplasms (MPN).  Dr. Mesa answered your... Continue Reading

Ovarian Cancer Talk: Participate in a Live Video Chat With the Experts from Roswell Park Cancer Institute (August 12, 2014)

Straight from Roswell Park Cancer Institute in Buffalo, N.Y., to your computer or mobile device, four leading experts in ovarian cancer will broadcast a live, interactive video chat from 6 to 7 p.m. on... Continue Reading

Weighing the Risks (August 12, 2014)

Exploring the Link Between Obesity and Cancer By Kari Bohlke, ScD “For the great majority of Americans who do not use tobacco, weight control, dietary choices, and levels of physical activity are the... Continue Reading

Large Independent Validation Study Validates Oncotype DX Prostate Cancer Test (August 11, 2014)

Genomic Health, Inc. announced positive preliminary results from an additional independent clinical validation study conducted by the Center for Prostate Disease Research (CPDR) demonstrating that the... Continue Reading

Exposure to Some Inflammatory Bowel Disease Drugs May Increase Leukemia Risk (August 8, 2014)

Thiopurines are an established treatment for inflammatory bowel disease (IBD) patients.  They are used to reduce inflammation and provide symptom relief.  Thiopurine immunosuppressive drugs have now... Continue Reading

Kyprolis Improves Progression-Free Survival in Multiple Myeloma (August 7, 2014)

Amgen announced that a planned interim analysis demonstrated that the Phase 3 clinical trial ASPIRE met its primary endpoint of progression-free survival (PFS).  Patients treated with Kyprolis® (carfilzomib)... Continue Reading

FDA Accepts Supplemental New Drug Application for Jakafi and Priority Review Granted for the Treatment of Polycythemia Vera (August 6, 2014)

The  U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Application (sNDA) for Jakafi® (ruxolitinib) as a potential treatment of patients with polycythemia vera... Continue Reading

Gilotrif combined with Erbitux Benefits Non-Small Cell Lung Cancer Patients Resistant to EGFR Inhibitors (August 5, 2014)

Researchers recently reported that a combination of the epidermal growth factor receptor (EGFR) targeted agents Gilotrif® (afatinib) and Erbitux® (cetuximab) were able to effectively shrink EGFR positive... Continue Reading

Pembrolizumab Appears Promising in Treatment of Non-Small Cell Lung Cancer (August 4, 2014)

Results from an ongoing Phase Ib study indicate that treatment with the experimental anti-PD-1 antibody pembrolizumab resulted in high response rates and slowed cancer progression in previously untreated... Continue Reading

Hepatitis C Cases Could Be Cured By Novel Oral Drug Regimen (July 31, 2014)

According to the results of two new clinical studies published in The Lancet, two new pill-only antiviral drug regimens for hepatitis C virus infection provide shorter and more effective treatment options... Continue Reading

Largest Study to Date of Pembrolizumab in Advanced Melanoma Shows Promising Activity (July 31, 2014)

The investigational anti-PD-1 antibody pembrolizumab is demonstrating promising survival rates among patients with advanced melanoma. Data from an ongoing Phase 1 trial of the drug were presented at the... Continue Reading

Investigational Drug Pembrolizumab Shows Anticancer Activity in Advanced Melanoma (July 30, 2014)

Recent findings reported in The Lancet indicate that the investigational drug pembrolizumab may be effective in patients with advanced melanoma that has progressed after treatment with Yervoy® (ipilimumab).[1]... Continue Reading

Jakafi® (ruxolitinib) Product Label Expanded to Include Overall Survival Data and Additional Safety and Dosing Information (July 30, 2014)

Jakafi is a prescription medicine approved by the U.S. Food and Drug Administration to treat people with intermediate or high-risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF... Continue Reading

More Cancer News

CancerConnect Cancer Commuity & Discussions


Cancer Types



Headline News by Cancer Type


Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Just another WordPress weblog
Facebook Twitter RSS